

**OptiBiotix Health plc
("OptiBiotix" or the "Company" or "the Group")**

Agreement with well-known Weight Management Company

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitutes announces the signing of a distribution agreement with a well-known direct selling weight management company (the "Distributor").

OptiBiotix will provide a range of SlimBiome® finished products under the Distributor's own branding and a WellBiome® product which will be included in their product range. The Distributor plans to launch in its biggest territory by sales first, which, if successful, will be followed by subsequent launches in other European countries. The products will be sold via a long standing and established distribution channel of consultants and via e-commerce. As part of this agreement, a first order is expected to be placed within the first three months of signing the agreement. Further information on the Distributor and brand will be announced on launch which OptiBiotix anticipates will be in H1 2026.

This agreement reflects the interest OptiBiotix is seeing in bringing functionality to weight management with traditional brands looking to leverage the interest in products which reduce hunger and cravings generated by the anti-obesity drugs. This agreement opens new opportunities to include science backed functional ingredients into well-known weight management brands.

Stephen O'Hara, CEO of OptiBiotix Health plc said "We are pleased to announce this agreement with a well-known and established weight management company. This agreement brings together the trust, loyalty, and customer base of a recognised brand with the science and functionality of SlimBiome®.

"Following the launch of anti-obesity drugs, natural, scientifically proven, non-drug alternatives to reduce hunger and cravings are actively being sought by consumers. This announcement demonstrates that the science and multiple human studies carried out on SlimBiome® is attracting the interest of major brands around the world."

The Directors of the Company are responsible for the release of this announcement.

For further information, please contact:

For further information, please contact: OptiBiotix Health plc

Neil Davidson, Chairman

Stephen O'Hara, Chief Executive

www.optibiotix.com

Contact via Walbrook below

Cairn Financial Advisers LLP (NOMAD and Broker)

Liam Murray / Jo Turner / Ludovico Lazzaretti

Tel: 020 7213 0880

Walbrook PR Ltd

Anna Dunphy

Mob: 07876 741 001

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as "believe", "could", "should" "envisage", "estimate", "intend", "may", "plan", "potentially", "expect", "will" or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

AGRFZGMRKLMGKZM